全文获取类型
收费全文 | 2268篇 |
免费 | 134篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 44篇 |
妇产科学 | 30篇 |
基础医学 | 458篇 |
口腔科学 | 44篇 |
临床医学 | 220篇 |
内科学 | 484篇 |
皮肤病学 | 39篇 |
神经病学 | 148篇 |
特种医学 | 133篇 |
外科学 | 320篇 |
综合类 | 7篇 |
预防医学 | 104篇 |
眼科学 | 54篇 |
药学 | 113篇 |
中国医学 | 5篇 |
肿瘤学 | 203篇 |
出版年
2023年 | 8篇 |
2022年 | 11篇 |
2021年 | 24篇 |
2020年 | 21篇 |
2019年 | 22篇 |
2018年 | 41篇 |
2017年 | 46篇 |
2016年 | 32篇 |
2015年 | 36篇 |
2014年 | 66篇 |
2013年 | 71篇 |
2012年 | 113篇 |
2011年 | 134篇 |
2010年 | 81篇 |
2009年 | 81篇 |
2008年 | 131篇 |
2007年 | 143篇 |
2006年 | 156篇 |
2005年 | 158篇 |
2004年 | 142篇 |
2003年 | 152篇 |
2002年 | 157篇 |
2001年 | 39篇 |
2000年 | 44篇 |
1999年 | 43篇 |
1998年 | 40篇 |
1997年 | 23篇 |
1996年 | 28篇 |
1995年 | 11篇 |
1994年 | 12篇 |
1993年 | 21篇 |
1992年 | 9篇 |
1991年 | 16篇 |
1990年 | 17篇 |
1989年 | 14篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1984年 | 7篇 |
1982年 | 15篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1975年 | 6篇 |
1974年 | 9篇 |
1941年 | 7篇 |
1939年 | 10篇 |
1938年 | 7篇 |
1932年 | 8篇 |
1926年 | 5篇 |
1924年 | 5篇 |
排序方式: 共有2411条查询结果,搜索用时 312 毫秒
31.
Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. 总被引:3,自引:0,他引:3
Martin R Müller Frank Grünebach Katrin Kayser Wichard Vogel Alessio Nencioni Wolfram Brugger Lothar Kanz Peter Brossart 《Clinical cancer research》2003,9(9):3448-3453
Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In a previous study (H. J. Bühring et al., Blood, 86: 1916-1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hematological malignancies including acute lymphoblastic leukemia (ALL). Here, we show that Her-2/neu-specific CTLs induced in vitro using peptide-pulsed dendritic cells efficiently lyse primary ALL blasts constitutively expressing both Her-2/neu and human leukocyte antigen A2 in an antigen-specific and MHC-restricted manner. Furthermore, we analyzed the feasibility of this approach in an autologous setting and induced Her-2/neu-specific CTLs using dendritic cells generated from peripheral blood mononuclear cells from an ALL patient that were pulsed with peptides or transfected with in vitro-transcribed Her-2/neu mRNA. Our data demonstrate that Her-2/neu could be used as a potential target for the application of Her-2/neu-directed treatment strategies in ALL including vaccination approaches. 相似文献
32.
33.
Peter Albers Roswitha Siener Sabine Kliesch Lothar Weissbach Susanne Krege Christoph Sparwasser Harald Schulze Axel Heidenreich Werner de Riese Volker Loy Erhard Bierhoff Christian Wittekind Rolf Fimmers Michael Hartmann 《Journal of clinical oncology》2003,21(8):1505-1512
PURPOSE: To prospectively assess potential risk factors for relapse in clinical stage I nonseminomatous germ cell tumors of the testis (CS I NSGCT). PATIENTS AND METHODS: From September 1996 to May 2002, 200 patients with CS I NSGCT were prospectively assigned to retroperitoneal lymph node dissection (RPLND), and risk factor assessment was performed within a multicenter protocol. One hundred sixty-five patients had an adequate minimum follow-up of 12 months (mean, 34.5 months) or had pathologic stage II. RESULTS: Pathologic stage II disease was found in 27.9% of patients. Only 0.6% of patients relapsed in the retroperitoneum after confirmation of pathologic stage I disease. With reference pathology, vascular invasion (VI) was most predictive of stage in multifactorial analysis (accuracy, 65.1%). However, the positive predictive value (PPV) of VI to predict patients who have metastatic disease or relapse during follow-up was only 52.7%. With absent VI, low-risk patients had a negative predictive value (NPV) of 76.9%. With a combination of several risk factors, the PPV increased to 63.6% and the negative predictive value increased to 86.5%. CONCLUSION: Even with an optimal combination of prognostic factors and reference pathology, more than one third of patients predicted to have pathologic stage II or relapse during follow-up will not harbor metastatic disease and, therefore, would be overtreated with adjuvant therapy. However, patients at low risk may be predicted at an 86.5% level, and thus, surveillance in highly compliant patients would be a valuable option. For high-risk patients, further reduction of adjuvant treatment is necessary. 相似文献
34.
35.
36.
Heymans Lothar Huber Martin Paeschke Norbert Palissa Harriet Keller-Stanislawski Brigitte 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2018,61(9):1088-1092
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Schulungsmaterial für Heilberufler und Patienten stellt eine wichtige Hilfe bei der sicheren Anwendung bestimmter... 相似文献
37.
AndrewJ. Stott Michel C. Maillard Vahri Beaumont David Allcock Omar Aziz Alexander H. Borchers Wesley Blackaby Perla Breccia Gillian Creighton-Gutteridge Alan F. Haughan Rebecca E. Jarvis Christopher A. Luckhurst Kim L. Matthews George McAllister Scott Pollack Elizabeth Saville-Stones Amanda J. Van de Poël Huw D. Vater Julie Vann Rachel Williams Dawn Yates Ignacio Muoz-Sanjun Celia Dominguez 《ACS medicinal chemistry letters》2021,12(3):380
Using an iterative structure–activity relationship driven approach, we identified a CNS-penetrant 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO, 12) with a pharmacokinetic profile suitable for probing class IIa histone deacetylase (HDAC) inhibition in vivo. Given the lack of understanding of endogenous class IIa HDAC substrates, we developed a surrogate readout to measure compound effects in vivo, by exploiting the >100-fold selectivity compound 12 exhibits over class I/IIb HDACs. We achieved adequate brain exposure with compound 12 in mice to estimate a class I/IIb deacetylation EC50, using class I substrate H4K12 acetylation and global acetylation levels as a pharmacodynamic readout. We observed excellent correlation between the compound 12 in vivo pharmacodynamic response and in vitro class I/IIb cellular activity. Applying the same relationship to class IIa HDAC inhibition, we estimated the compound 12 dose required to inhibit class IIa HDAC activity, for use in preclinical models of Huntington’s disease. 相似文献
38.
Diffusion parameter mapping with the combined intravoxel incoherent motion and kurtosis model using artificial neural networks at 3 T
下载免费PDF全文
![点击此处可从《NMR in biomedicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Marco Bertleff Sebastian Domsch Sebastian Weingärtner Jascha Zapp Kieran O'Brien Markus Barth Lothar R. Schad 《NMR in biomedicine》2017,30(12)
Artificial neural networks (ANNs) were used for voxel‐wise parameter estimation with the combined intravoxel incoherent motion (IVIM) and kurtosis model facilitating robust diffusion parameter mapping in the human brain. The proposed ANN approach was compared with conventional least‐squares regression (LSR) and state‐of‐the‐art multi‐step fitting (LSR‐MS) in Monte‐Carlo simulations and in vivo in terms of estimation accuracy and precision, number of outliers and sensitivity in the distinction between grey (GM) and white (WM) matter. Both the proposed ANN approach and LSR‐MS yielded visually increased parameter map quality. Estimations of all parameters (perfusion fraction f, diffusion coefficient D, pseudo‐diffusion coefficient D*, kurtosis K) were in good agreement with the literature using ANN, whereas LSR‐MS resulted in D* overestimation and LSR yielded increased values for f and D*, as well as decreased values for K. Using ANN, outliers were reduced for the parameters f (ANN, 1%; LSR‐MS, 19%; LSR, 8%), D* (ANN, 21%; LSR‐MS, 25%; LSR, 23%) and K (ANN, 0%; LSR‐MS, 0%; LSR, 15%). Moreover, ANN enabled significant distinction between GM and WM based on all parameters, whereas LSR facilitated this distinction only based on D and LSR‐MS on f, D and K. Overall, the proposed ANN approach was found to be superior to conventional LSR, posing a powerful alternative to the state‐of‐the‐art method LSR‐MS with several advantages in the estimation of IVIM–kurtosis parameters, which might facilitate increased applicability of enhanced diffusion models at clinical scan times. 相似文献
39.
Niehues T Horneff G Michels H Höck MS Schuchmann L;Working Groups Pediatric Rheumatology Germany 《Rheumatology international》2005,25(3):169-178
Juvenile idiopathic arthritis (JIA) is the most common diagnosis in children and adolescents with rheumatic disorders. In many children and adolescents, JIA is successfully treated with non-steroidal anti-inflammatory drugs (NSAID) and physiotherapy. However, in a significant number of cases the disease is resistant to this therapy, and treatment with second line disease-modifying antirheumatic drugs (DMARDs) is required. Methotrexate (MTX) is frequently referred to as first-choice second-line agent for the treatment of JIA. To increase drug safety, the Working Groups for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and Pediatric Rheumatology Austria have initiated the formulation of evidence-based recommendations. Evidence is based on consensus expert meetings, a MEDLINE search with the key words Methotrexate and juvenile arthritis limited to age 0–18 years, standard textbooks and review articles, data from the central registry of the German Research Center for Rheumatic Diseases (Deutsches Rheumaforschungszentrum Berlin DRFZ), experience with MTX in adults with rheumatoid arthritis (RA), and recommendations of the German Society of Rheumatology (DGRh). Based on these data, evidence and recommendations are graded, and evidence-based recommendations for the use of MTX in children and adolescents with rheumatic disease are presented.Section Pharmacotherapy of the Working Group Pediatric Rheumatology Germany and Austria: I. Foeldvari; J.P. Haas, A. Haeffner, D. Hobusch,G. Horneff, A. Hospach, R. Keitzer, G. Klaus, M. Metzler, H. Michels, T. Niehues, I. Pilz, M. Sailer Höck, M. Schöntube, L. Schuchmann, K. Schumacher, H.W. Seyberth, E. Siemers, A. Urban, E. Weißbarth-Riedl. Working Group Pediatric Rheumatology North-Rhine-Westfalia: S. Benseler, G. Bürk, S. Fahl, I. Foeldvari, D. Föll, M. Frosch, G. Ganser, S. Kastner, I. Kleine, E. Lainka, K. Mönkemöller, J. Neubert, U. Neudorf, T. Niehues, J. Roth, S. Seeliger, N. Wagner, R. Wieland, H. Winowski. 相似文献
40.
Recruitment of DNA methyltransferase I to DNA repair sites 总被引:2,自引:0,他引:2
Mortusewicz O Schermelleh L Walter J Cardoso MC Leonhardt H 《Proceedings of the National Academy of Sciences of the United States of America》2005,102(25):8905-8909
In mammalian cells, the replication of genetic and epigenetic information is directly coupled; however, little is known about the maintenance of epigenetic information in DNA repair. Using a laser microirradiation system to introduce DNA lesions at defined subnuclear sites, we tested whether the major DNA methyltransferase (Dnmt1) or one of the two de novo methyltransferases (Dnmt3a, Dnmt3b) are recruited to sites of DNA repair in vivo. Time lapse microscopy of microirradiated mammalian cells expressing GFP-tagged Dnmt1, Dnmt3a, or Dnmt3b1 together with red fluorescent protein-tagged proliferating cell nuclear antigen (PCNA) revealed that Dnmt1 and PCNA accumulate at DNA damage sites as early as 1 min after irradiation in S and non-S phase cells, whereas recruitment of Dnmt3a and Dnmt3b was not observed. Deletion analysis showed that Dnmt1 recruitment was mediated by the PCNA-binding domain. These data point to a direct role of Dnmt1 in the restoration of epigenetic information during DNA repair. 相似文献